[CAS NO. 353519-63-8] HLM006474
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [353519-63-8]
Catalog
SLK-S8963
Brand
Selleck
CAS
353519-63-8
DESCRIPTION [353519-63-8]
Overview
| MDL | MFCD02168344 |
|---|---|
| Molecular Weight | 399.48 |
| Molecular Formula | C25H25N3O2 |
| SMILES | OC1=C2N=C(C)C=CC2=CC=C1C(C3=CC=C(OCC)C(C)=C3)NC4=NC=CC=C4 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5033 mL | 12.5163 mL | 25.0325 mL |
| 5 mM | 0.5007 mL | 2.5033 mL | 5.0065 mL |
| 10 mM | 0.2503 mL | 1.2516 mL | 2.5033 mL |
| 50 mM | - | - | - |
Description
HLM006474 is a small molecule pan- inhibitor that inhibits DNA binding to E2F4 with IC50 of 29.8 µM in A375 cells. HLM006474 induces a reduction in cell proliferation and an increase in apoptosis. The CDK/Rb/E2F pathway is commonly disrupted in lung cancer, and HLM006474 is shown to have efficacy in lung cancer.
Targets
| E2F4 [1] (Cell-free assay) |
| 29.8 μM |
In vitro
Treatment of multiple cell lines with HLM006474 results in the loss of intracellular E2F4 DNA-binding activity within hours. Overnight exposure to HLM006474 results in down regulation of total E2F4 protein as well as known E2F targets. The effects of HLM006474 treatment on different cell lines varies, but includes a reduction in cell proliferation and an increase in apoptosis. HLM006474 reduces the viability of both SCLC and NSCLC lines with a biological IC50 that varies between 15 and 75 mM, but with no significant difference between the groups.
References
Powered by Arctom Copyright © 2026 Arctom.
All rights reserved.